Biocryst Pharmaceuticals (BCRX) EBT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 12.16% |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | 103.79% |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | 24.03% |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 45.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.27% |
| Mar 31, 2026 | -139.21% |
| Dec 31, 2025 | 76.20% |
| Sep 30, 2025 | 31.92% |
| Jun 30, 2025 | 28.30% |
| Mar 31, 2025 | 26.21% |
| Dec 31, 2024 | -18.74% |
| Sep 30, 2024 | 38.85% |
| Jun 30, 2024 | 33.85% |
| Mar 31, 2024 | 18.33% |
| Dec 31, 2023 | -3.19% |
| Sep 30, 2023 | 8.07% |
| Jun 30, 2023 | -24.48% |
| Mar 31, 2023 | -11.91% |
| Dec 31, 2022 | -194.15% |
| Sep 30, 2022 | -2.80% |
| Jun 30, 2022 | -15.75% |
| Mar 31, 2022 | -32.94% |
| Dec 31, 2021 | 16.83% |
| Sep 30, 2021 | -24.83% |